Diese Präsentation wurde erfolgreich gemeldet.
Die SlideShare-Präsentation wird heruntergeladen. ×

Immunomodulation Induced by Echinacea

Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Anzeige
Nächste SlideShare
Echinacea and immune system
Echinacea and immune system
Wird geladen in …3
×

Hier ansehen

1 von 60 Anzeige

Immunomodulation Induced by Echinacea

Herunterladen, um offline zu lesen

Keywords: echinacea, immunomodulation, antifungal,antiviral, anti-oxidant, anti inflammation, anti immuno-suppresant, clinical use, pregnancy, precaution.

Keywords: echinacea, immunomodulation, antifungal,antiviral, anti-oxidant, anti inflammation, anti immuno-suppresant, clinical use, pregnancy, precaution.

Anzeige
Anzeige

Weitere Verwandte Inhalte

Ähnlich wie Immunomodulation Induced by Echinacea (20)

Anzeige

Weitere von Ariyanto Harsono (20)

Anzeige

Immunomodulation Induced by Echinacea

  1. 1. Immunomodulation Induced by Echinacea Prof DR Dr Ariyanto Harsono SpA(K)
  2. 2. Ag IL-12/ IL-1 TCR MHC-IIT h0 Th-2 IL-1 TNF-β, IFN-γ IL-2, IFN-γ B-Cell IL-4 IL-5 SEL PLASMA SEL MEMORI IL-6 IL-10 CTL MHC-I I L-2 IFN-γ SEL-NK SEL-NK AKTIF FC-R L SEL ABNORMAL SITOTOKSIN SEL-LISIS Sel Abnormal Memory Cells ADCC Prof DR.dr. Ariyanto Harsono SpAK FASL Th.1 Introduction
  3. 3. Dr. Ariyanto Harsono SpAK 3 Prof DR.dr. Ariyanto Harsono SpAK
  4. 4. B-T Cell Interaction Prof DR.dr. Ariyanto Harsono SpAK
  5. 5. B-T Cell Interaction Th1 IgG IgM IgA IL-12 IFN-g Prof DR.dr. Ariyanto Harsono SpAK
  6. 6. Prof DR.dr. Ariyanto Harsono SpAK INNATE iMMUNITY
  7. 7. Prof DR.dr. Ariyanto Harsono SpAK INNATE Immunity,,,,,
  8. 8. IgA TReg TGF-b Prof DR.dr. Ariyanto Harsono SpAK Imunitas Humoral
  9. 9. IgG Th1 Cell Imunitas Humoral….. Prof DR.dr. Ariyanto Harsono SpAK
  10. 10. IgG Th1 Cell Imunitas Humoral….. CTL DTH Prof DR.dr. Ariyanto Harsono SpAK DNA /Whole cell Vaccine
  11. 11. Effectors mechanisms against extracellular pathogens OPSONISATION Bacteria in extracellular space Fc receptor binding + Ab OPSONISATION Phagocytosis Prof DR.dr. Ariyanto Harsono SpAK
  12. 12. Effectors mechanisms against extracellular pathogens COMPLEMENT Activation Bacteria in extracellular space + Ab & COMPLEMENT Lysis Complement & Phagocytosis Fc receptor binding Opsonisation Prof DR.dr. Ariyanto Harsono SpAK
  13. 13. Clinical Features of immune deficiency • Syndromes • Failure to Thrive • Bacterial infection • Viral Infection • Opportunistic infection • Chronic diarrhea • Blood abnormality • Skin lesions Prof DR.dr. Ariyanto Harsono SpAK
  14. 14. Prof DR.dr. Ariyanto Harsono SpAK
  15. 15. Prof DR.dr. Ariyanto Harsono SpAK
  16. 16. Prof DR.dr. Ariyanto Harsono SpAK
  17. 17. Prof DR.dr. Ariyanto Harsono SpAK
  18. 18. Prof DR.dr. Ariyanto Harsono SpAK
  19. 19. Prof DR.dr. Ariyanto Harsono SpAK
  20. 20. Prof DR.dr. Ariyanto Harsono SpAK
  21. 21. Prof DR.dr. Ariyanto Harsono SpAK
  22. 22. Prof DR.dr. Ariyanto Harsono SpAK
  23. 23. Prof DR.dr. Ariyanto Harsono SpAK
  24. 24. Prof DR.dr. Ariyanto Harsono SpAK
  25. 25. Prof DR.dr. Ariyanto Harsono SpAK
  26. 26. Prof DR.dr. Ariyanto Harsono SpAK
  27. 27. Prof DR.dr. Ariyanto Harsono SpAK
  28. 28. Prof DR.dr. Ariyanto Harsono SpAK
  29. 29. MANAGEMENT Prof DR.dr. Ariyanto Harsono SpAK Hematopoietic growth factors Methisoprinol Echinacea Interferon propolis
  30. 30. History • Native Americans may have used Echinacea for more than 400 years to treat infections and wounds and as a general cure-all • Its use began to decline in the US after the introduction of antibiotics • Increasingly popular in Germany throughout the 20th century. Most of the scientific research on Echinacea has been conducted in Germany • Today, people use Echinacea to shorten the common cold and reduce symptoms, such as sore throat, cough, and fever Am Fam Phycisian 2003;67:77-80 Univ of Maryland Medical Center Wikipedia, the free encyclopedia
  31. 31. • Native to eastern and central North America • echinos is Greek for hedgehog • Named for the prickly scales in its large conical seed head, resembles the spines of an angry hedgehog
  32. 32. Active constituents • Vary slightly according to species and include caffeic acid derivatives (primarily echinocoside), flavonoids, essential oils, polyacetylenes, alkylamides, and polysaccharides • No single constituent has been found to be primarily responsible for Echinacea's immune-stimulating effect; rather they appear to all work together to accomplish this Am Fam Phycisian 2003;67:77-80 Alternative Medicine Review 2001
  33. 33. General uses • Several laboratory and animal studies suggest that Echinacea contains active substances that enhance the activity of the immune system • Many herbalists recommend Echinacea to help boost the immune system and help the body fight infections • Other functions: relieve pain, reduce inflammation, and have hormonal, antiviral, and antioxidant effect Am Fam Phycisian 2003;67:77-80 Univ of Maryland Medical Center Wikipedia, the free encyclopedia
  34. 34. Echinacea Pharmacodynamic of Echinacea is: o Stimulates lymphokine production by limphocyte, increases TNF-a, IL-1, IL-6, IL-10, o Enhances cellular immunity in healthy children or immunodeficiency, increases NK cell activity, and inhibits hialuronidase. o Echinacea works especially in non specific immune system. o Evidence until recently there is no disadvantage in long-term use, and does not aggravate asthma and auto-immune disease. o Enhancing phagocytosis of granulocyte of human in vitro. o Increases phagocytosis of candida albicans by granulocyte and monocyte, as well as increases leukocytes count: granular, neutophile and macrophage. Prof DR.dr. Ariyanto Harsono SpAK IMMUNO-POTENTIATOR
  35. 35. A total of 26 controlled clinical trials (18 randomized, 11 double-blind) were identified; 6 of these involved testing three different mono-extracts, and 20 involved testing three different preparations also containing other ingredients. Nineteen trials studied the efficacy of the prophylactic or curative treatment of infections; 4 trials the reduction of side-effects of antineoplastic therapies and 3 trials the modulation of various laboratory immune parameters. The primary authors claimed that 30 of the 34 treatment strategies showed a superior efficacy to those of the control groups. The methodological quality of most studies was low and only 8 trials scored more than half of the maximum possible score points. Melchart D, Linde K, Worku F, Bauer R, Wagner H. Immunomodulation with echinacea — a systematic review of controlled clinical trials. Phytomedicine 1994, 1: 245-254
  36. 36. Immunomodulation Many studies investigating immunomodulatory properties have been conducted with different Echinacea species, extracts, and plant parts. However, there is little agreement on which chemical constituents are responsible for activity on the immune system. Enhanced macrophage function, stimulation of cytokine production (including certain interleukins and tumor necrosis factor alpha), enhanced natural-killer function, and increased mean circulating total white blood cell counts have all been demonstrated in vitro.
  37. 37. ANTI-INFLAMMATION ACTIVITY Echinacea purpurea is one of the main medicinal Echinacea species and have long been used to treat infections, to aid in wound healing and to enhance the immune system. Alkamides and caffeic acid derivatives are potent anti – inflammatory agents present in Echinacea . Echinacea-derived alkamides have immunomodulatory and anti-inflammatory activity. E. purpurea (EP) have been used for wound healing, pain relief and alleviation of cold symptoms. Alcohol extracts of Echinacea offers anti-inflammatory effects through inhibition of production of inflammatory mediators tumor necrosis factor-alpha (TNF-α) and nitric oxide (NO).
  38. 38. Prostaglandin E2 (PGE2) is a critical inflammatory mediator that is produced through the arachidonic acid cascade. The anti-inflammatory role of Echinacea is also mediated through own regulation of cyclooxygenase-1 and cyclooxygenase-2 through suppression of Prostaglandin E2 activation. COX-1 and COX-2 catalyze the reaction converting arachidonic acid, released by phospholipase A, to Prostaglandin E2. Wagner has reported lipoxygenase- inhibiting anti-inflammatory activity attributable to one of E. purpurea’s isobutylamides, dodecatetraenoic acid. .
  39. 39. Alcohol extracts of Echinacea are composed of two classes of natural chemicals lipophilic alkamides and water-soluble caffeic acid derivatives. Caffeic acid derivatives have an antihyaluronidase activity. An inhibition of hyaluronidase leads to accumulation of enough hyaluronan in the extracellular matrix for wound caffeic acid derivative, showed a healing process characterized by reduced inflammatory response and higher hyaluronan content. These data indicate that Echinacea presents a clear antiinflammatory activity that may promote wound tissue recovery.
  40. 40. ANTI-OXIDANT ACTIVITY Echinacea was found to be a very potent antioxidant38. Arachidonic acid metabolism and prostaglandin E2 production were reduced by several E. purpurea. Alcohol extracts of Echinacea are typically composed of two classes of natural chemicals, lipophilic alkamides and water-soluble caffeic acid derivatives. Caffeic acid derivatives are effective antioxidants in free radical generation systems and have an anti hyaluronidase activity. Enhancement of free radical scavenging activity has been shown by laboratories in the U.S. and Canada. Hu and Kitts investigated anti-oxidant and free radicals scavenging activity, including suppression of oxidation of human low-density lipoprotein. .
  41. 41. ANTI IMMUNOSUPPRESSANT Echinacea products are the most popular herbal immunostimulants in North America and Europe. In 1997 Echinacea may be best known as an immunostimulant. There have been numerous reports of immunomodulatory properties in various preparations derived from different parts of several species of Echinacea. A series of studies in mice using purified polysaccharides from Echinacea plant cell cultures showed a stimulatory effect when applied to immune cells in culture or injected intraperitoneally into mice. Mice with suppressed immunity due to treatment with cyclophosphamide or cyclosporin also had an increase in these immune functions when given purified polysaccharides from Echinacea.
  42. 42. These studies suggest that Echinacea stimulates immune functions in healthy or in immunosuppressed animals. These immunologically active polysaccharides did not stimulate all immune cells. B cells were not activated, nor did the B cells produce more antibodies to sheep red blood cells. Apparently, purified polysaccharides from E. purpurea act on the nonspecific branch of immunity. Recent studies have been shown that rhinoviruses could stimulate the transcription of various immuneresponse genes in different types of cells. Furthermore the expression of cytokine genes and some of their secreted products in bronchial epithelial cells could be reversed by Echinacea preparations. Several animal and human studies have suggested that Echinacea stimulates neutrophil and macrophage phagocytic function. Other scientific studies suggests that the Echinacea purpurea possesses nonspecific, short-term immune system stimulant properties.
  43. 43. Anti Fungal The Extract of E. purpurea has been shown to have antifungal activities in a series of in vitro experiments testing activity against various Candida species, and various Saccharomyces cerevisiae, Candida albicans the most common fungal cause of human skin disease. Antimicrobial actions were observed in various E. purpurea root and herb extracts. Other laboratories have also reported anti Candida activity of extract of Echinacea purpurea. Phagocytosis of Candida by ex vivo human macrophages and natural killer cells was found to be enhanced following exposure to extracts of both E. purpurea and Gingseng. Mouse macrophage activity against Candida has also been observed to be stimulated by E. purpurea polysaccharide exposure. The polysaccharide rich Echinacea purpurea extract was found to decrease the infection and death rates of immunosuppressed mice infected with Candida.
  44. 44. Coeugniet and Kuhnast demonstrated a human clinical trial testing an expressed juice of E. purpurea (Echinacin®) for ability to effect recurrent vaginal yeast infections. They found Echinacin®-treated groups demonstrated increased skin reactivity and decreased recurrence of vaginal candidiasis over the 6-month monitoring period while 60% of controls got new infections, only 5–17% of women in the treatment groups were diagnosed with recurrent vaginal infections (P < 0.05).
  45. 45. ANTI VIRAL ACTIVITY Biological activity of the chemical Components of E. purpurea have been characterized, Echinacea has antiviral and anti bacterial activity and they have found that cultured cells infected with virus and exposed to E. purpurea juice demonstrated an increased rate of presentation of viral antigen. Benzalkonium chloride and phytochemicals derived from Echinacea purpurea was found to have antiviral activity against herpes virus in a human cell model. Echinacea purpurea was also very effective against influenza virus.
  46. 46. Skwarek et al revealed that the extract of E. purpurea has been found to inhibit viral replication in animal cell viral culture models. Eilmes demonstrated that complex has more viral-infection- inhibititory activity fractions. Polysaccharide derived from Echinacea purpurea has been shown to stimulate macrophage activity and several functions related to cytokine production and groups of phenolic compounds and alkamides, which have demonstrated antiviral and antifungal properties, respectively. These activities could be related to the reports that some E. purpurea preparations were able to prevent or control upper respiratory infections (URIs). Recent study described a human trial testing the efficacy of Echinacea in preventing colds induced by a cultured rhinovirus. There are no reports on E.Purpurea in relation to HIV.
  47. 47. Immune stimulations Echinacea's immune-stimulating properties are quite complex and are attributed to the combined effect of several of its constituents • directly stimulated white blood cell production •  phagocytic activity •  NK cell activity •  antibody-dependent cellular cytotoxicity, •  tumor necrosis factor-alpha (TNF-a) •  complement activity •  cytokine production •  enzyme: cyclo-oxygenase, lypo-oxygenase, hyaluronidase Am Fam Phycisian 2003;67:77-80 Alternative Medicine Review 2001 Infect Immune 1994:46:845-9
  48. 48. Uses & efficacy • Upper respiratory infection, prevention • Upper respiratory infection, treatment • Urinary tract infection • Fungal infections Am Fam Phycisian 2003;67:77-80
  49. 49. Acute respiratory infection • Same (early) symptoms: fever, cough, coryza • Upper – lower; nose – alveoli; AURI – ALRI • Involving lower respiratory part – fast breathing & difficult breathing • fever, cough, coryza  symptoms of ARI due to influenza virus: Influenza like illness (ILI) / influenza like symptoms / influenza like syndrome
  50. 50. Precautions • Herbs contain active substances that may trigger side effects and interact with other herbs, supplements, or medications • In Germany, use of Echinacea is restricted to no longer than eight weeks at a time • Echinacea loses its effectiveness after eight consecutive weeks regular users of this herb • People with tuberculosis, leukemia, diabetes, connective tissue disorders, multiple sclerosis, HIV or AIDS, any autoimmune diseases, or, possibly, liver disorders should not take Echinacea Univ of Maryland Medical Center
  51. 51. Side effects & contraindications • In rare cases, echinacea may cause allergic reactions ranging from a mild rash to anaphylaxis • People with asthma and allergies may be at an increased risk for developing these adverse reactions • When taken by mouth, echinacea may cause temporary numbing and tingling on the tongue. • Evidence suggests that the use of echinacea during pregnancy does not increase the risk of birth defects or other pregnancy-related health problems Univ of Maryland Medical Center
  52. 52. Echinacea & pregnancy positive Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. The Motherisk Program, Division of Clinical Pharmacology /Toxicology, The Hospital for Sick Children, University Ave, Toronto, Canada CONCLUSIONS: This first prospective study suggests that gestational use of echinacea during organogenesis is not associated with an increased risk for major malformations. Arch Intern Med. 2000 Nov 13;160(20):3141-3.
  53. 53. Echinacea & pregnancy positive Safety and efficacy of echinacea (E. angustafolia, e. purpurea and e. pallida) during pregnancy and lactation. Department of Clinical Pharmacology and Toxicology, University of Toronto, Canada. CONCLUSIONS: Echinacea is non-teratogenic when used during pregnancy. Caution with using Echinacea during lactation until further high quality human studies can determine its safety. Can J Clin Pharmacol. 2006 Fall;13(3):e262- 7.
  54. 54. Echinacea & pregnancy positive Conclusion: A recent Mother-risk study showed that use of echinacea during the first trimester of pregnancy was NOT associated with increased risk of major malformations Canadian Fam Phycisian 2001;47:1727-8
  55. 55. Echinacea & pregnancy negative Influence of Echinacea purpurea intake during pregnancy on fetal growth and tissue angiogenic activity. Dept. of Obstetrics and Gynecology, Medical University of Warsaw, Poland. Conclusion, there is some possibility that pharmaceuticals containing Echinacea purpurea might influence fetal development in human also, because they may interfere with embrional angiogenesis, and should not be recommended for pregnant women. Folia Histochem Cytobiol. 2007;45 Suppl 1:S35-9.
  56. 56. Echinacea & pregnancy negative Safety and efficacy of herbal remedies in obstetrics - review and clinical implications. Dept of Chemistry/Centre for Pharmacy, Univ of Bergen, Allégaten 41, 5007 Bergen, Norway. CONCLUSIONS: there is limited documentation on the safety and efficacy of many herbs commonly used during pregnancy. Midwifery. 2009 Sep 24.
  57. 57. Safety • GI upset • No aggravation of allergy • US FDA category © Prof DR.dr. Ariyanto Prof DR.dr. Ariyan tHoa Hrsaornsoon Sop ASpKAK
  58. 58. Ag IL-12/ IL-1 APC MHC-II Th0 Conclusion Th-2 Th.1 IL-1 TNF-β, IFN-γ IL-2, IFN-γ B-Cell IL-4 IL-5 SEL PLASMA SEL MEMORI IL-6 IL-10 CTL MHC-I I L-2 IFN-γ SEL-NK Sel Abnormal FASL SEL-NK AKTIF FC-R L L SITOTOKSIN SEL ABNORMAL SEL-LISIS Memory Cells ADCC Echinacea Prof DR.dr. Ariyanto Harsono SpAK
  59. 59. REFERENCES 1. McGregor RL, The taxonomy of the genus Echinacea (Compositae). University of Kansas Science Bulletin, 48:113–142, (1968). 2. Binns SE, Baum BR and Arnason JT, A taxonomic revision of Echinacea (Asteraceae: Heliantheae). SystBot, 27:610–632, (2002a). 3. Foster S, “Echinacea: Nature’s Immune Enhancer”. Rochester, VT: Healing Arts Press, (1991). 4. Bauer, R. and H. Wagner. Echinacea species as potential immunostimulatory drugs. In:H. Wagner and N.R. Farnsworth (eds.), Economic and medicinal plant research.Vol. 5. Academic Press, New York, 1991, p. 253–321. 5. Brevoort P, The Booming U.S. Botanical Market: A New Overview. HerbalGram, 44:33–46, (1998). 6. B. Galambosi. Cultivation in Europe. In: S.C. Miller and H. Yu (eds.), Echinacea: The genus Echinacea, CRC Press, Boca Raton, Fla., 2004, pp. 29–52. 7. W. Letchamo, L.V. Polydeonny, N.O. Gladisheva, T.J. Arnason, J. Livesey, and D.V.C. Awang. Factors affecting Echinacea quality. In: J. Janick and A. Whipkey (eds.), Trends in new crops and new uses, ASHS Press, Alexandria Va, 2002, pp. 514–521
  60. 60. Thank You

×